Experimental mouse tumour models: what can be learnt about human cancer immunology? (Q82767780)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Experimental mouse tumour models: what can be learnt about human cancer immunology? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

Glenn Dranoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

2 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Immunology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

61-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

PD-1 and its ligands in tolerance and immunity

17 January 2020

cites work

1 reference

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

31 March 2020

1 reference

Immune therapy for cancer

31 March 2020

1 reference

Animal models of tumor immunity, immunotherapy and cancer vaccines

31 March 2020

1 reference

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

31 March 2020

1 reference

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

31 March 2020

1 reference

Bioluminescent imaging of melanoma in live mice

31 March 2020

1 reference

Calreticulin exposure dictates the immunogenicity of cancer cell death

31 March 2020

1 reference

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

31 March 2020

1 reference

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

31 March 2020

1 reference

The makings of a tumor rejection antigen

31 March 2020

1 reference

Eradication of established tumors by CD8+ T cell adoptive immunotherapy

31 March 2020

1 reference

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

31 March 2020

1 reference

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

31 March 2020

1 reference

Vaccination for treatment and prevention of cancer in animal models.

31 March 2020

1 reference

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

31 March 2020

1 reference

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice

31 March 2020

1 reference

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

31 March 2020

1 reference

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

31 March 2020

1 reference

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

31 March 2020

1 reference

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

31 March 2020

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

31 March 2020

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

31 March 2020

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

31 March 2020

1 reference

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

31 March 2020

1 reference

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

31 March 2020

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

31 March 2020

1 reference

Natural innate and adaptive immunity to cancer

31 March 2020

1 reference

Cancer-related inflammation

31 March 2020

1 reference

Immunity, Inflammation, and Cancer

31 March 2020

1 reference

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

31 March 2020

1 reference

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

31 March 2020

1 reference

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

31 March 2020

1 reference

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis

31 March 2020

1 reference

Immunosuppressive strategies that are mediated by tumor cells

31 March 2020

1 reference

Regulatory T cells, tumour immunity and immunotherapy

31 March 2020

1 reference

Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression

31 March 2020

1 reference

A dual role for the immune response in a mouse model of inflammation-associated lung cancer

31 March 2020

1 reference

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

31 March 2020

1 reference

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

31 March 2020

1 reference

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

31 March 2020

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

31 March 2020

1 reference

A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages

31 March 2020

1 reference

Leukocyte composition of human breast cancer

31 March 2020

1 reference

Macrophage diversity enhances tumor progression and metastasis

31 March 2020

1 reference

Dual roles for immunity in gastrointestinal cancers

31 March 2020

1 reference

Humanized mice for modeling human infectious disease: challenges, progress, and outlook.

31 March 2020

1 reference

Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation

31 March 2020

1 reference

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

31 March 2020

1 reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

31 March 2020

1 reference

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

31 March 2020

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host

31 March 2020

1 reference

12 December 2020

Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene.

1 reference

12 December 2020

Immunity to methylcholanthrene-induced sarcomas

1 reference

12 December 2020

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors

1 reference

12 December 2020

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI3129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22134155%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference